News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,095 Results
Type
Article (42265)
Company Profile (233)
Press Release (694586)
Multimedia
Podcasts (104)
Webinars (21)
Section
Business (205447)
Career Advice (2100)
Deals (35700)
Drug Delivery (140)
Drug Development (81868)
Employer Resources (174)
FDA (16604)
Job Trends (15064)
News (348027)
Policy (32934)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2632)
Accelerated approval (55)
ADA (44)
Adcomms (31)
Allergies (193)
Alliances (49718)
ALS (227)
Alzheimer's disease (1847)
Antibody-drug conjugate (ADC) (522)
Approvals (17085)
Artificial intelligence (729)
ASCO (328)
Autoimmune disease (347)
Automation (63)
Bankruptcy (364)
Best Places to Work (11673)
BIO (68)
BIOSECURE Act (20)
Biosimilars (235)
Biotechnology (151)
Bladder cancer (204)
Brain cancer (75)
Breast cancer (807)
Cancer (6336)
Cardiovascular disease (507)
Career advice (1787)
Career pathing (45)
CAR-T (361)
CDC (59)
Celiac Disease (3)
Cell therapy (973)
Cervical cancer (56)
Clinical research (71764)
Collaboration (2210)
Commercialization (1)
Company closure (5)
Compensation (1522)
Complete response letters (85)
COVID-19 (2782)
CRISPR (116)
C-suite (1247)
Cystic fibrosis (158)
Data (8670)
Decentralized trials (3)
Denatured (29)
Depression (175)
Dermatology (98)
Diabetes (671)
Diagnostics (7049)
Digital health (64)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (362)
Drug pricing (206)
Drug shortages (31)
Duchenne muscular dystrophy (309)
Earnings (92334)
Editorial (69)
Employer branding (21)
Employer resources (156)
Events (120951)
Executive appointments (1135)
FDA (20656)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (22)
Frontotemporal dementia (35)
Funding (1858)
Gene editing (246)
Generative AI (62)
Gene therapy (756)
GLP-1 (1101)
Government (4792)
Grass and pollen (6)
Guidances (421)
Healthcare (19227)
Hematology (192)
HIV (90)
Huntington's disease (62)
IgA nephropathy (113)
Immunology and inflammation (304)
Immuno-oncology (107)
Indications (222)
Infectious disease (3149)
Inflammatory bowel disease (222)
Inflation Reduction Act (14)
Influenza (142)
Intellectual property (320)
Interviews (340)
IPO (16705)
IRA (50)
Job creations (3674)
Job search strategy (1471)
JPM (59)
Kidney cancer (21)
Labor market (112)
Layoffs (579)
Leadership (42)
Legal (8010)
Liver cancer (103)
Longevity (35)
Lung cancer (838)
Lymphoma (478)
Machine learning (65)
Management (62)
Manufacturing (1164)
Marketing (4)
MASH (211)
Medical affairs (1)
Medical device (14022)
Medtech (14196)
Mergers & acquisitions (20320)
Metabolic disorders (1660)
mRNA (231)
Multiple sclerosis (201)
NASH (17)
Neurodegenerative disease (460)
Neuropsychiatric disorders (109)
Neuroscience (3490)
Neurotech (1)
NextGen: Class of 2026 (6568)
Non-profit (4574)
Now hiring (83)
Obesity (764)
Opinion (302)
Ovarian cancer (241)
Pain (266)
Pancreatic cancer (354)
Parkinson's disease (394)
Partnered (36)
Patents (644)
Patient recruitment (773)
Peanut (67)
People (60112)
Pharmaceutical (54)
Pharmacy benefit managers (34)
Phase 1 (22376)
Phase 2 (31614)
Phase 3 (23526)
Pipeline (9902)
Policy (336)
Postmarket research (2584)
Preclinical (9489)
Press Release (64)
Prostate cancer (336)
Psychedelics (58)
Radiopharmaceuticals (346)
Rare diseases (1190)
Real estate (6009)
Recruiting (71)
Regulatory (25957)
Reports (56)
Research institute (2445)
Resumes & cover letters (363)
Rett syndrome (46)
RNA editing (25)
RSV (90)
Schizophrenia (184)
Series A (315)
Series B (234)
Service/supplier (11)
Sickle cell disease (121)
Special edition (26)
Spinal muscular atrophy (170)
Sponsored (48)
Startups (3664)
State (2)
Stomach cancer (18)
Supply chain (134)
Tariffs (87)
The Weekly (73)
Vaccines (1164)
Venture capital (121)
Weight loss (489)
Women's health (138)
Worklife (21)
Date
Today (42)
Last 7 days (474)
Last 30 days (2241)
Last 365 days (30378)
2026 (16424)
2025 (30207)
2024 (35243)
2023 (40134)
2022 (51258)
2021 (55807)
2020 (54209)
2019 (46722)
2018 (35161)
2017 (32213)
2016 (31625)
2015 (37715)
2014 (31438)
2013 (26466)
2012 (28680)
2011 (29401)
2010 (27436)
Location
Africa (756)
Alabama (93)
Alaska (7)
Arizona (367)
Arkansas (14)
Asia (40151)
Australia (6584)
California (14043)
Canada (3979)
China (1497)
Colorado (598)
Connecticut (613)
Delaware (436)
Europe (87068)
Florida (2119)
Georgia (448)
Hawaii (3)
Idaho (64)
Illinois (1157)
India (100)
Indiana (634)
Iowa (25)
Japan (601)
Kansas (134)
Kentucky (51)
Louisiana (58)
Maine (77)
Maryland (1669)
Massachusetts (10068)
Michigan (377)
Minnesota (758)
Mississippi (6)
Missouri (149)
Montana (33)
Nebraska (30)
Nevada (150)
New Hampshire (84)
New Jersey (3675)
New Mexico (30)
New York (3692)
North Carolina (1775)
North Dakota (9)
Northern California (7101)
Ohio (422)
Oklahoma (23)
Oregon (41)
Pennsylvania (2790)
Puerto Rico (31)
Rhode Island (52)
South America (1127)
South Carolina (89)
South Dakota (2)
Southern California (5572)
Tennessee (231)
Texas (2254)
United States (49546)
Utah (418)
Vermont (2)
Virginia (346)
Washington D.C. (81)
Washington State (1117)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
737,095 Results for "forty seven inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
May 29, 2026
·
10 min read
Press Releases
Cellares Accepted to FDA’s Inaugural Manufacturing PreCheck Cohort, the Only Cell Therapy Platform Among Seven Companies Nationwide
June 30, 2026
·
5 min read
Press Releases
Parexel to Showcase Seven Research Posters and Debut New Hematology Playbook at the European Hematology Association Congress 2026
June 10, 2026
·
6 min read
Press Releases
Ainnocence Proposes a Seven-Rule Governance Framework and Value Scorecard for AI-Driven Drug Discovery
CEO and Founder Dr. Lurong Pan calls on the AI pharmaceutical industry to set boundaries for the algorithm, pairing executable safety rules with an honest, two-dimensional method for measuring what a model actually contributes
June 1, 2026
·
1 min read
Press Releases
Factor Bioscience to Deliver Seven Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
May 6, 2026
·
4 min read
Press Releases
Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years
May 8, 2026
·
5 min read
Press Releases
Forge Biologics Announces Seven Presentations at the American Society of Gene and Cell Therapy (ASGCT) 29th Annual Meeting
May 11, 2026
·
3 min read
Press Releases
Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)
April 21, 2026
·
16 min read
Press Releases
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
May 29, 2026
·
19 min read
Alzheimer’s disease
Roche’s Next-Gen Alzheimer’s Antibody Clears or Reduces Amyloid Plaques in Seven Months
In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months of treatment, representing what B. Riley Securities called a “paradigm shift” to first-generation FDA-approved antibodies.
July 28, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 73,710
Next
